mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222

与Spikevax®COVID-19疫苗mRNA-1273.222相比，mRNA-1283诱导了更强大的免疫反应

Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against influenza and COVID-19, mRNA-1083

下一代mRNA疫苗的设计提供了更长保质期和储存优势的潜力，并为针对流感和新型冠状病毒19，mRNA-1083的联合疫苗铺平了道路

CAMBRIDGE, MA / ACCESSWIRE / March 26, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine..

马萨诸塞州剑桥/ACCESSWIRE/2024年3月26日/Moderna，Inc.（纳斯达克：MRNA）今天宣布，该公司的下一代COVID-19疫苗MRNA-1283已成功达到其3期临床试验的主要终点，证明与Moderna许可的COVID-19疫苗MRNA-1273.222相比，对SARS-CoV-2的免疫应答更高。

'We are excited to announce our fourth infectious disease vaccine program with positive Phase 3 data, further validating our robust mRNA platform,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'mRNA-1283 is a critical component of our combination vaccine against flu and COVID-19, mRNA-1083, and this milestone gives us confidence in our ability to bring this much needed vaccine to market.'.

Moderna首席执行官斯特凡·班塞尔（StéphaneBancel）说：“我们很高兴宣布我们的第四个传染病疫苗计划，该计划的第三阶段数据呈阳性，进一步验证了我们强大的mRNA平台。”mRNA-1283是我们针对流感和新型冠状病毒19（COVID-19，mRNA-1083）的联合疫苗的关键组成部分，这一里程碑让我们对将这种急需的疫苗推向市场的能力充满信心。”

In the NextCOVE (NCT05815498) Phase 3 pivotal trial, mRNA-1283 was shown to elicit a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2, compared to mRNA-1273.222. Importantly, this benefit was most acutely seen in participants over the age of 65 years, the population that remains at highest risk for severe outcomes from COVID-19.

在NextCOVE（NCT05815498）3期关键试验中，与mRNA-1273.222相比，mRNA-1283显示出对Omicron BA.4/BA.5和SARS-CoV-2原始病毒株的更高免疫应答。重要的是，这种益处在65岁以上的参与者中最为明显，这些人群仍然是新型冠状病毒肺炎严重后果的最高风险人群。

The most common solicited local adverse event was injection site pain. The most common solicited systemic adverse events included headache, fatigue, myalgia and chills..

最常见的局部不良事件是注射部位疼痛。最常见的全身不良事件包括头痛，疲劳，肌痛和寒战。

The NEXTCove clinical trial is a randomized, observer-blind, active-controlled study of approximately 11,400 individuals aged 12 years and older in the United States, United Kingdom and Canada. mRNA-1283 was found to have a similar safety profile to Moderna's approved COVID-19 vaccines.

NEXTCove临床试验是一项随机，观察者盲，主动对照研究，在美国，英国和加拿大约有11400名12岁及以上的个体。发现mRNA-1283与Moderna批准的COVID-19疫苗具有相似的安全性。

The storage, shelf life and pre-filled syringe presentation of mRNA-1283 could alleviate healthcare provider burden and potentially increase access into new settings to serve public health. A detailed analysis of the Phase 3 clinical trial data for mRNA-1283 will be shared at the Company's Vaccines Day event on March 27 and presented at upcoming scientific conferences..

mRNA-1283的储存，保质期和预填充注射器呈现可以减轻医疗保健提供者的负担，并可能增加进入新环境以服务公共卫生的机会。对mRNA-1283的3期临床试验数据的详细分析将在3月27日该公司的疫苗日活动上分享，并在即将举行的科学会议上介绍。

About Moderna

关于Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines..

Moderna是mRNA医学领域的领导者。通过mRNA技术的进步，Moderna正在重新想象药物的制造方式，并改变我们如何为每个人治疗和预防疾病。通过十多年来在科学、技术和健康的交叉点工作，该公司以前所未有的速度和效率开发了药物，包括最早和最有效的新型冠状病毒疫苗之一。

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines.

Moderna的mRNA平台为传染病、免疫肿瘤学、罕见病和自身免疫性疾病的治疗和疫苗的开发提供了支持。凭借独特的文化和由Moderna价值观和心态驱动的全球团队，以负责任的方式改变人类健康的未来，Moderna努力通过mRNA药物为人们带来尽可能大的影响。

For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn..

有关Moderna的更多信息，请访问modernatx.com，并通过X（以前的Twitter）、Facebook、Instagram、YouTube和LinkedIn与我们联系。

Spikevax® is a registered trademark of Moderna.

Spikevax®是Moderna的注册商标。